MediGene
12
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.3%
1 terminated/withdrawn out of 12 trials
91.7%
+5.2% vs industry average
17%
2 trials in Phase 3/4
9%
1 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
Role: lead
Study Evaluating the Pharmacokinetic Profile of Novel Formulations of RHUDEX®
Role: lead
Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers
Role: lead
EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients
Role: lead
Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage
Role: lead
Study Evaluating the Pharmacokinetic Profile of RhuDex® in a Tablet Formulation
Role: lead
A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases
Role: lead
G207 Followed by Radiation Therapy in Malignant Glioma
Role: lead
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
Role: lead
Phase-I Study Evaluating the Pharmacokinetic Profile of RhuDex®
Role: lead
Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts
Role: lead
Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer
Role: lead
All 12 trials loaded